HUTCHMED reports 2025 financial results and updates
HUTCHMED reports 2025 financial results, with global sales growth driven by overseas expansion and new indications in China. Net profit of $457 million from core business and asset sales.
HUTCHMED's savolitinib NDA accepted for gastric cancer
HUTCHMED's savolitinib NDA for MET-amplified gastric cancer accepted by China's NMPA for priority review, potentially becoming China's first selective MET inhibitor for this indication.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.